PharmaAsia Recap

July 3, 2018  Source: FiercePharma 128

Biocon receives ‘clean plant bill’ from FDA for Bangalore
The Food and Drugs Administration (FDA) approved Biocon's Bangalore plant, where the biosimilars were prepared under partnerships with Mylan and Novartis. The FDA previously placed the plant under observation, which led to the delay in considering Mylan-partnered biosimilar of Roche’s Herceptin and rejection of Neulasta biosimilar.

China’s C-Bridge invests $20 million in Nuance Biotech
China's C-Bridge Capital has invested $20 million in Shanghai-based Nuance Biotech in order to support future in-license deals with an additional $15 million for the acquisition of new products such as Chinese rights to Pacira Pharmaceuticals’ products like Exparel.

Adlai Nortye raises $50 million
Adlai Nortye Biopharma, an immune-oncology company in China, has raised $50 million. The company has in-licensed Oncolytics’ Reolysin and Eisai’s EP4 antagonist E7046. Reolysin would be entering phase 3 trial in breast cancer whereas, E7046 would become first-in-class.

Takeda on Shire buyout and competition from Roche’s Hemlibra
Investors raised concerns to Christophe Weber, the CEO of Takeda on how sustainable sales from Shire’s hemophilia unit would remain in the face of competition from Roche’s Hemlibra. Roche is planning to expand Hemlibra’s application at a significant discount rate to Shire’s Adynovate.

By Ddu
Share: